Pomalidomide and lenalidomide regulate erythropoiesis and fetal hemoglobin production in human CD34⁺ cells
J. Clin. Invest. Laure A. Moutouh-de Parseval, et al. 118:248 doi:10.1172/JCI32322 [Go to this article.]

Figure 6
HU is synergistic with pomalidomide and lenalidomide in increasing HbF expression during erythroid differentiation. CD34⁺ cells were differentiated toward erythroid lineage in the presence of increasing concentrations of pomalidomide, lenalidomide, and HU at 10 μM alone or in combination. After 6 days, HbF expression was evaluated by flow cytometry. (A) Histograms of the percentage of cells expressing HbF in response to single or combination treatments are represented. (B) Histograms represent the MFI relative to the cell number. The experiments were repeated on samples from at least 2 different donors with similar results.